Natera, Inc. $NTRA Shares Purchased by IQ EQ FUND MANAGEMENT IRELAND Ltd

IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its position in Natera, Inc. (NASDAQ:NTRA) by 57.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,940 shares of the medical research company’s stock after buying an additional 9,424 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in Natera were worth $4,176,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in shares of Natera by 2.3% in the second quarter. Vanguard Group Inc. now owns 12,676,653 shares of the medical research company’s stock valued at $2,141,594,000 after acquiring an additional 282,826 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Natera by 44.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 10,625,785 shares of the medical research company’s stock valued at $1,795,125,000 after purchasing an additional 3,263,822 shares in the last quarter. Geode Capital Management LLC increased its position in Natera by 7.0% during the 2nd quarter. Geode Capital Management LLC now owns 2,552,725 shares of the medical research company’s stock worth $430,640,000 after purchasing an additional 166,768 shares during the period. Franklin Resources Inc. increased its position in Natera by 20.6% during the 2nd quarter. Franklin Resources Inc. now owns 1,937,647 shares of the medical research company’s stock worth $327,346,000 after purchasing an additional 330,696 shares during the period. Finally, AQR Capital Management LLC raised its stake in shares of Natera by 44.6% during the 2nd quarter. AQR Capital Management LLC now owns 1,726,750 shares of the medical research company’s stock worth $291,717,000 after buying an additional 532,769 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera News Summary

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Regulatory/catalyst: Natera submitted a PMA to the FDA for Signatera CDx to detect minimal residual disease in bladder cancer after positive phase‑3 results — a potential pathway to a companion‑diagnostic revenue stream and better reimbursement/clinical adoption if approved. Natera files Signatera CDx PMA (Zacks)
• Neutral Sentiment: Routine insider trims: Several non‑executive insiders (e.g., Solomon Moshkevich, John Fesko) sold modest, single‑digit percentages of their positions; these look like routine liquidity actions but add incremental supply. InsiderTrades report on recent sales
• Negative Sentiment: Material CEO sale: CEO Steven Chapman sold 85,299 shares (~40% reduction) on Feb 2 for roughly $19.7M — a large, high‑visibility block that investors commonly view as a negative signal and that likely amplified downward pressure. CEO Form 4 (SEC)
• Negative Sentiment: Additional executive selling: CEO Chapman sold another 4,725 shares (Feb 3) and CFO Michael Burkes Brophy sold 6,939 shares (Feb 3), further trimming insider ownership and reinforcing near‑term selling pressure. CEO additional Form 4 CFO Form 4 (SEC)

Natera Trading Down 4.1%

NASDAQ:NTRA opened at $197.08 on Friday. The company has a market capitalization of $27.26 billion, a P/E ratio of -86.06 and a beta of 1.64. The firm has a 50-day moving average price of $234.15 and a two-hundred day moving average price of $195.75. Natera, Inc. has a twelve month low of $125.38 and a twelve month high of $256.36.

Natera (NASDAQ:NTRA) last announced its earnings results on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). The company had revenue of $592.18 million for the quarter, compared to analyst estimates of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. Natera’s quarterly revenue was up 34.7% compared to the same quarter last year. During the same quarter last year, the company posted ($0.26) EPS. On average, equities research analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Steven Leonard Chapman sold 4,725 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $230.77, for a total value of $1,090,388.25. Following the completion of the transaction, the chief executive officer owned 123,156 shares of the company’s stock, valued at approximately $28,420,710.12. The trade was a 3.69% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider John Fesko sold 3,594 shares of the company’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $231.02, for a total transaction of $830,285.88. Following the completion of the transaction, the insider owned 178,081 shares in the company, valued at approximately $41,140,272.62. This trade represents a 1.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 455,899 shares of company stock worth $106,475,440. 5.63% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on NTRA shares. Morgan Stanley lifted their price target on Natera from $220.00 to $265.00 and gave the company an “overweight” rating in a research note on Monday, December 1st. Barclays boosted their target price on shares of Natera from $230.00 to $270.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. UBS Group increased their price target on shares of Natera from $218.00 to $280.00 and gave the company a “buy” rating in a report on Tuesday, November 18th. Evercore ISI raised their price objective on shares of Natera from $190.00 to $250.00 and gave the company an “outperform” rating in a research note on Friday, November 7th. Finally, BTIG Research increased their target price on shares of Natera from $230.00 to $260.00 and gave the company a “buy” rating in a report on Friday, December 5th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Natera currently has a consensus rating of “Moderate Buy” and an average price target of $249.20.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.